Hair Loss, Diagnosis, And Treatment Planning

This review discusses the potential link between androgenetic alopecia and COVID-19 severity, examining the role of androgens and relevant treatments, but reports no new clinical results.

Nutraceuticals like Ashwagandha and Astaxanthin may help with hair loss, but supplement regulation is challenging.

The authors describe a case where a 24-year-old woman experienced diffuse hair loss, likely telogen effluvium, after bariatric surgery, suggesting nutritional deficiencies and multifactorial causes may contribute to this condition.

This study in Italy observed telogen effluvium and trichodynia as common hair-related complications following COVID-19 infection, raising questions about underlying hair follicle biology and potential receptor involvement.

This review proposes that inconsistent findings in androgenic alopecia research are due to variable biopsy location, hair diameter diversity, and hair follicle miniaturization, and suggests ways to improve study methods.

This review discusses the use of platelet-rich plasma for treating female androgenetic alopecia, reporting that it shows high patient satisfaction and improved quality of life in affected women.

This study reviews the types of alopecia associated with lupus erythematosus and discusses treatment challenges, highlighting that non-scarring alopecia is specific to systemic lupus while chronic cutaneous lupus can cause scarring alopecia, with topical corticosteroids and oral antimalarials as primary treatments for cutaneous lupus erythematosus.

This study found that lower serum ferritin levels were significantly associated with telogen effluvium compared to healthy subjects and may serve as a potential biomarker for its diagnosis.

This study demonstrates that dermal white adipose tissue regulates human hair growth and pigmentation through hepatocyte growth factor secretion, highlighting potential therapeutic targets for hair-related disorders.

This review found that platelet-rich plasma therapy improved hair growth and thickness in most studies on alopecia, with the highest improvement seen when combined with Minoxidil.

This article discusses the potential association between stress, poor sleep, and telogen effluvium during the COVID-19 pandemic, highlighting the possible role of substance P, but reports no new clinical results.

This study reported that autologous whole fat injection in the scalp considerably increased hair growth in patients with androgenetic alopecia.

This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

This review outlines the current state of freeze-dried platelet-rich plasma (FD-PRP) research, emphasizing its use in wound healing, lumbar fusion, knee conditions, and dentistry, but reports no new clinical findings.

This study concluded that leucocyte-rich PRP has a continuous stimulatory effect on human fibroblast cells, enhancing their proliferation, migration, and impacting gene expression of the extracellular matrix and adhesion molecules.

This study found that combining platelet-rich plasma therapy with minoxidil was more effective in treating androgenetic alopecia in men than either treatment alone.

This study found that concentrated nanofat, used alone or with decellularized nanofat, may enhance hair growth in mice by activating dermal papilla cells and the anagen phase.

This study found that increasing energy fluence, session duration, and using pulsed irradiation significantly enhance hair regrowth in androgenetic alopecia when using low-level laser therapy, while the number of diodes does not affect outcomes.

In this study, researchers found that severe androgenic alopecia in hospitalized men was associated with a higher likelihood of testing positive for COVID-19.

This study found that combining micro-needling, low-level laser therapy, and autologous non-activated platelet-rich plasma increased hair density in patients with androgenic alopecia over the treatment period.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

This systematic review study found that platelet-rich plasma treatment may improve hair density and diameter in women with androgenetic alopecia, although the findings are limited by the small sample sizes and pilot nature of the included studies.

This review discusses the causes, diagnosis, and treatment of telogen effluvium and reports no new clinical findings; the authors underscore the importance of identifying and eliminating causative factors.

Quarantine stress likely worsened hair loss in women, but video consultations helped manage their condition and reduce anxiety.

This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.

This systematic review and meta-analysis found that platelet-rich plasma treatments improved hair density and thickness in people with androgenetic alopecia, without serious adverse effects.

This study found that combining microneedling with 5% minoxidil improved hair growth in Chinese men with androgenetic alopecia, possibly through activating the Wnt/β-catenin signaling pathway.

This case report describes a patient with secondary syphilis exhibiting distinct dermoscopic features, including moth-eaten alopecia and an erythematous background more pronounced than previously reported.

This study found that serum ischemia-modified albumin levels were significantly higher in patients with telogen effluvium compared to healthy controls, suggesting a potential role of oxidative stress in the condition's pathogenesis.

In this systematic review, tSVF-based therapy demonstrated favorable outcomes for various pathologies, including aged skin and osteoarthritis, with low incidence of adverse events, while highlighting the need for further research into optimal protocols and mechanisms of action.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.

LLLT is a safe, promising hair loss treatment, but more research needed.

This study reported that early-onset androgenetic alopecia primarily affects Chinese males aged 21–30, with a high likelihood of paternal inheritance.

This study found that early male hair loss treatment with Puregraft fat and low-dose adipose-derived regenerative cells increased terminal hair counts at 24 weeks compared to a saline control, indicating promise for androgenetic alopecia treatment.

In this study, autologous non-activated platelet-rich plasma was associated with greater hair re-growth than autologous activated platelet-rich plasma over long-term follow-up.

In this study, PRP injections showed comparable effectiveness to triamcinolone for alopecia areata, with a significant decrease in SALT score at one interval, and 12.5% of patients in the PRP group experienced excellent hair regrowth compared to none in the triamcinolone group.

This article discusses the causes, diagnosis, and treatment options for female pattern hair loss, emphasizing the role of topical minoxidil as a primary treatment, but provides no new clinical results.

This study found that platelet-rich plasma was effective for hair regrowth in women with androgenic alopecia, though less so than minoxidil, but it was associated with improved quality of life responses.

Exosomes from stem cells may help treat hair loss.

This essay discusses telogen effluvium, the issues surrounding its diagnosis and differentiation from other forms of hair loss, and emphasizes the need for empathetic patient care; it reports no new clinical findings.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This clinical study reported that while both 0.01% and 0.03% bimatoprost significantly improved eyebrow density and diameter in patients with eyebrow hypotrichosis, the 0.03% concentration was more clinically preferred by patients.

This study found that microneedling improved hair density and thickness with minimal side effects in patients with androgenetic alopecia and telogen effluvium.

This study found that type 2 diabetes was associated with a higher risk of severe central scalp hair loss in African American women.

This review discusses the advancements in intraoperative stem cell therapies and highlights their potential to improve hair regrowth, but it reports no new clinical results.

This study found that hair thickness and density increased after treatment with human follicle mesenchymal stem cells and platelet rich plasma, associated with enhanced Wnt signaling and platelet derived growth factors.

This review assessed the effectiveness of various treatments for frontal fibrosing alopecia and found that intralesional steroids and 5α-reductase inhibitors showed the most positive outcomes in slowing or halting hair loss, though the lack of placebo-controlled studies and consistent outcome measures limits definitive conclusions.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

This literature review suggests that fractional laser therapies may positively impact hair regrowth in androgenic alopecia, though current evidence is mostly limited to small studies and case reports, highlighting a need for more comprehensive randomized controlled trials to confirm their efficacy and safety.

This study found that using a fractional CO2 laser in combination with minoxidil significantly increased hair count and thickness in Egyptian men with androgenetic alopecia.

In this study, researchers suggest that laser-assisted drug delivery could enhance the administration of platelet-rich plasma, and potentially bimatoprost or minoxidil, for patients with androgenetic alopecia by ensuring uniform placement in the dermis without injection pain.

The authors concluded that dermal white adipose tissue, influenced by factors like light irradiation, plays a significant role in modulating hair follicle cycles and could be targeted for hair growth treatments.

This review discusses the potential role of vitamins and minerals in managing non-scarring alopecia but reports no clinical results; the authors advocate for further controlled trials to explore these relationships.

This review discusses the role of androgens in women's skin-related conditions like acne, hirsutism, and female pattern hair loss, noting the lack of dermatology guidelines for when to pursue endocrinologic evaluation.

This study found that platelet-rich plasma significantly increased hair count, density, and the percentage of anagen hairs in patients with androgenetic alopecia, but these improvements did not correlate with platelet or growth factor levels.

This study reports that while topical minoxidil treatment showed a response in less than 40% of men after 24 weeks, oral finasteride stopped hair loss in over 80% of patients at 12 months; perceived sexual side effects of the latter may limit its use.

This review suggests that hair transplantation may be a viable treatment option for certain primary scarring alopecias, although findings should be interpreted cautiously due to possible publication bias favoring positive results.

This review discusses trichoscopic features of hair disorders in individuals with dark skin phototypes and reports no new clinical results; the authors emphasize the need for more specific diagnostic criteria for these populations.

In this randomized, double-blind trial, researchers observed that low-level laser therapy led to significantly greater hair regrowth on treated areas compared to a sham treatment in patients with androgenetic alopecia over 24 weeks, suggesting it as a potentially effective and safe option.

This review summarizes the clinical, trichoscopic, and histopathological features of alopecia types associated with cutaneous and systemic lupus erythematosus and explores their links to disease activity, but it reports no new clinical results.

This review discusses the causes and diagnosis of traction alopecia, emphasizing education for high-risk populations as there is currently no cure, and presents no new clinical findings.

This study found that a single injection of platelet-rich stroma significantly increased hair density in men with androgenetic alopecia within 6 to 12 weeks, with no reported side effects.

This study suggests that minoxidil may enhance hair growth by stimulating adipose-derived stem cell motility and growth factor secretion, promoting dermal papilla cell proliferation and accelerating anagen induction.

This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.

This study concluded that 12 sessions of fractionated thulium laser treatment improved hair density and thickness in patients with pattern hair loss, with further benefits from adding a growth factor solution post-treatment.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This review identifies FDA-cleared home-use photobiomodulation devices for androgenetic alopecia treatment and highlights their excellent safety profile but notes the lack of long-term comparative studies.

This review examines the effects of adipose-derived stem cells and their secreted factors on hair growth stimulation in laboratory and animal models, suggesting their potential as therapeutic agents for hair loss treatment.

In this study, patients with mild to moderate androgenetic alopecia who received platelet-rich plasma injections with microneedling showed improvements in hair growth and thickness, as well as high satisfaction, over a three-month period compared to conventional therapy non-responders.

This review highlights that in children, hair loss can be attributed to diverse conditions like alopecia areata and tinea capitis, and stresses the importance of a holistic approach to diagnosis and management, including psychosocial support due to limited effective treatments.

This study found that scalp injection of fat enriched with stem cells may offer a promising alternative for treating early genetic alopecia in both men and women.

This review suggests that platelet-rich plasma may be effective in increasing hair density in patients with androgenetic alopecia, but more research is needed to determine the best treatment protocol.

This case study reports the first documentation of the intermittent nature of chronic telogen effluvium and suggests a link between emotional stress and hair shedding severity.

This study found that combining microneedling with PRP and topical minoxidil (5%) significantly improved hair growth in men with androgenetic alopecia compared to using minoxidil alone.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This letter provides no study results about minoxidil 3% lotion for beard enhancement but instead shares author and affiliation details for the published research.

This study reports that the duration of hair loss is positively associated with the severity of central centrifugal cicatricial alopecia in African-American women.

This study found that repeated microneedle stimulation in mice promoted hair growth and increased the expression of hair-growth-related genes, suggesting potential therapeutic uses for alopecia.

This abstract reviews the symptom of trichodynia, a painful scalp sensation linked to hair loss, and highlights its potential connection to inflammation but reports no new research findings.

This study found that platelet-rich plasma injections significantly increased hair count and density in patients with male pattern hair loss without major side effects, suggesting it may be a safe and effective treatment option.

In this study, spironolactone was reported to stabilize or improve female pattern hair loss in 74.3% of treated women, especially those with signs of hyperandrogenism.

This case report described cosmetically significant hair regrowth in a 39-year-old woman with permanent chemotherapy-induced alopecia after continuous oral minoxidil use.

This review discusses the potential applications of prostaglandin F2α analogs for certain types of alopecia and hypopigmentation, but reports no new experimental results.

This review discusses the various triggers and diagnostic challenges in determining the cause of telogen effluvium-related hair loss, without providing new clinical results.

This study found that PRP injections may improve hair density and reduce hair loss in patients with androgenetic alopecia without significant side effects, but further research is needed to confirm efficacy.

In this study, micropigmentation was reported to be an effective method for camouflaging hair loss and scalp scars in Korean patients, with high satisfaction in 42 out of 43 cases.

This study suggests that minoxidil 2% lotion is a safe and effective treatment for enhancing eyebrows, showing better results than placebo after 16 weeks.

This review discusses the causes, clinical presentation, and management of anagen effluvium, emphasizing its psychological impact and the need for empathy and practical support, but reports no new results.

This study found that adding microneedling to minoxidil treatment significantly improved hair growth in men with androgenetic alopecia compared to minoxidil alone across all assessed measures.

This study found that topical melatonin solution was associated with positive effects on hair density and reduction in hair loss for androgenetic alopecia, with good tolerability reported in several clinical trials.

This study found that while calcium can substitute for the Vitamin D receptor in maintaining epidermal keratinocyte differentiation, it cannot compensate for hair follicle dysfunction caused by the absence of the receptor.

This study found that PRP combined with dalteparin and protamine microparticles may enhance hair growth by increasing hair thickness compared to PRP alone.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

Iron deficiency might be linked to hair loss, but more research is needed.

This study found a high prevalence of central hair loss among African American women and associated it with diabetes mellitus type 2, bacterial scalp infections, and hairstyles causing traction.

This guideline reviews the diagnosis of androgenetic alopecia and offers expert consensus recommendations tailored to males, females, and adolescents, but reports no new clinical results.

This review discusses the advantages and limitations of various hair loss evaluation methods but reports no new results; it emphasizes the importance of cautious interpretation for these diagnostic tools.

This study found that trichoscopy criteria can distinguish female androgenic alopecia from chronic telogen effluvium, with specific features achieving 98% diagnostic specificity.

In this study, treatment with finasteride 1 mg/day for five years significantly reduced the likelihood of further visible hair loss in men with androgenetic alopecia compared to placebo.

Early diagnosis and personalized treatment are crucial for managing different types of alopecia effectively.

This review discusses the complexities of diagnosing and treating iron deficiency related to nutritional anemia and hair loss, concluding that routine screening and supplementation for hair loss are not yet supported by sufficient evidence.

This review discusses the diagnosis and treatment of iron deficiency, its potential link to hair loss, and emphasizes the importance for dermatologists to understand these aspects; it reports no new findings.

This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

This study suggests that stress negatively affects hair growth by inducing inflammation and early hair cycle transitions in mice, which might inform strategies for managing stress-related hair loss in humans.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

This study reports that the TrichoScan method effectively measures hair growth parameters and detected significant improvements in hair counts and thickness in men with androgenetic alopecia after finasteride treatment.

In this study, female androgenic alopecia (grade II or III on Ludwig's scale) was found to be common among Finnish women aged 63, and several markers of insulin resistance, along with paternal history of alopecia, were associated with an increased risk.

This article discusses various mechanisms for promoting hair growth in pattern hair loss and highlights the challenge of balancing short-term measurable results in trials with the need for long-term efficacy data.

This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.

This article discusses the biologic and psychosocial significance of hair, the current limitations in hair growth drugs, and anticipates future therapies based on advancing hair follicle research.

This study found that 2% ketoconazole shampoo improved hair density and anagen follicle proportion in androgenic alopecia similarly to minoxidil treatment, suggesting a potential role for Malassezia in inflammation.

Photographic documentation crucial for evaluating hair growth in androgenetic alopecia.

This study found that androgenetic alopecia causes significant psychological distress, particularly in women, who exhibit a more negative body image and less adaptive functioning compared to controls.

Minoxidil treatment may cause hair loss.